It's a pretty attractive property. Four billion dollar consumer businesses don't go on the market every day.
By our calculation, Pfizer's consumer business has an implied market value of US$4.6 billion ($6.9 billion) but could be sold for 2 to 2.5 times that amount, or US$10 billion.
By our calculation, Pfizer's consumer business has an implied market value of $4.6 billion but could be sold for 2 to 2.5 times that amount, or $10 billion.
They can get a good price for it and it's probably undervalued in their portfolio. It's not so much about them getting out of that business much as it's about unleashing shareholder value.